GE HealthCare Technologies Inc. - Common Stock (GEHC)
82.40
+0.26 (0.32%)
GE HealthCare Technologies Inc. is a leading global medical technology and digital solutions innovator focused on improving patient outcomes through advanced healthcare solutions
The company develops and manufactures a wide range of diagnostic imaging systems, monitoring devices, and healthcare IT services that empower healthcare providers to deliver accurate and efficient patient care. Through its commitment to innovation, GE HealthCare supports clinicians and patients by providing tools that enhance diagnostic capabilities, streamline workflows, and facilitate data-driven decision-making in an increasingly complex healthcare environment.
NVIDIA Corp. establishes center for accelerated quantum research in Boston, along with collaborations with Alphabet, Google, GE Healthcare, IBM, CrowdStrike & Yum! Brands to drive advancements in AI and transform industries like healthcare and cybersecurity.
GE HealthCare (Nasdaq: GEHC) today announced a collaboration with NVIDIA at GTC 2025, expanding the existing relationship between the two companies to focus on pioneering innovation in autonomous imaging, beginning with autonomous X-ray technologies and autonomous applications within ultrasound.
GE HealthCare (Nasdaq: GEHC) today announced the launch of the AltiX AI.i edition of Mac-Lab™, CardioLab™ and ComboLab™. The AltiX AI.i editions are designed to improve the user experience, elevating workflow in the cardiac catheterization (cath) lab and supporting even the most complex electrophysiology (EP) procedures. These latest editions offer new features that can streamline workflow and enhance interoperability, while upholding strong cybersecurity standards.
Goldman Sachs upgrades GE Healthcare to Buy, raising its price target to $100, as analysts see market stabilization and China sales recovering faster than expected.
As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the medical devices & supplies - imaging, diagnostics industry, including Lantheus (NASDAQ:LNTH) and its peers.
GE HealthCare (Nasdaq: GEHC) today announced its new Genesis solutions, a portfolio of cloud enterprise imaging software-as-a-service (SaaS) solutions. Four features will be offered when commercially released – edge, storage, vendor neutral archive and data migration.i These cloud solutions, are designed to help enhance healthcare organizations’ efficiency and precision, streamline workflows, and optimize the use of capital and IT resources.
Nvidia’s reign in AI may not last forever. Discover three overlooked AI stocks poised for growth as they leverage AI breakthroughs to drive future gains.
GE HealthCare (Nasdaq: GEHC), a leading global healthcare solutions provider, today announced that Yihao Zhang, president and CEO, China, will retire from the company effective July 1, 2025. Will Song, a Johnson & Johnson veteran for over 20 years, has been named GE HealthCare’s new president and CEO, China, and will join the company on April 1, 2025, ahead of leading the region starting July 1 following Yihao’s departure.
GE HealthCare (Nasdaq: GEHC) today unveiled Freelium™,ii a next-generation sealed magnet platform, that aims to enable high-quality Magnetic Resonance (MR) imaging with less than 1% of helium used in conventional magnet technology to help support diagnostic accuracy and sustainability goals. Debuting at the European Congress of Radiology (ECR), Freelium marks the evolution of GE HealthCare’s established lightweight intelligent platform magnet technology, which was first introduced in 2020, now with over 2,000 installations worldwide at 1.5T and 3.0T magnetic fields.
GE HealthCare (Nasdaq: GEHC) has delivered the first patient doses of Flyrcado™ (flurpiridaz F 18) injection, a first-of-its-kind unit dose positron emission tomography myocardial perfusion imaging (PET MPI) agent for the detection of coronary artery disease (CAD), at early adopter imaging centers in the US. This milestone follows the recent FDA approval of Flyrcado, which is indicated for patients with known or suspected CAD, and delivers higher diagnostic efficacy compared to single-photon emission computed tomography (SPECT) MPI, the predominant procedure used in nuclear cardiology today.
The US market is yet to commence its session on Thursday, but let's get a preview of the pre-market session and explore the top S&P500 gainers and losers driving the early market movements.
Curious about the top performers within the S&P500 index in the middle of the day on Thursday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.
Healthcare technology company GE HealthCare Technologies (NASDAQ:GEHC) met Wall Street’s revenue expectations in Q4 CY2024, with sales up 2.2% year on year to $5.32 billion. Its non-GAAP profit of $1.45 per share was 14.8% above analysts’ consensus estimates.
